Advertisement

Epidemiology and Public Health Implications of the Opioid Crisis

  • Michael D. MendozaEmail author
  • Holly Ann Russell
Chapter
  • 48 Downloads

Abstract

Opioid overdose deaths continue to grow nationwide. Simultaneously, efforts to understand and promote the appropriate management of substance use and pain are expanding. The goals of improved treatment for patients and responding to the opioid overdose epidemic are both priorities. Pediatric and adult care providers must reconsider their approach to pain and substance use disorder in light of the current opioid epidemic. This chapter summarizes general principles about opioid use disorder, presents an overview of the epidemiology and public health implications of the contemporary opioid crisis, and closes with an overview of current approaches to prevention, treatment, and harm reduction.

Keywords

Opioid Opioid use disorder Substance use disorder Overdose Addiction Pain Pain management Medication-assisted treatment 

References

  1. 1.
    Murphy SL, Xu JQ, Kochanek KD, Arias E. Mortality in the United States, 2017. NCHS data brief, no 328. Hyattsville: National Center for Health Statistics; 2018.Google Scholar
  2. 2.
    Wide-ranging online data for epidemiologic research (WONDER). Atlanta: CDC, National Center for Health Statistics; 2017. Available at http://wonder.cdc.gov.
  3. 3.
    American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th ed. Arlington: American Psychiatric Publishing; 2013.CrossRefGoogle Scholar
  4. 4.
    Van Zee A. The promotion and marketing of oxycontin: commercial triumph, public health tragedy. Am J Public Health. 2009;99(2):221–7.CrossRefGoogle Scholar
  5. 5.
    Dowell D, Haegerich TM, Chou RCDC. Guideline for prescribing opioids for chronic pain – United States, 2016. JAMA. 2016;315(15):1624–45.CrossRefGoogle Scholar
  6. 6.
    Dasgupta N, Beletsky L, Ciccarone D. Opioid crisis: no easy fix to its social and economic determinants. Am J Public Health. 2018;108(2):182–6.CrossRefGoogle Scholar
  7. 7.
    Cicero TJ, Ellis MS, Surratt HL, Kurtz SP. The changing face of heroin use in the United States: a retrospective analysis of the past 50 years. JAMA Psychiat. 2014;71(7):821–6.CrossRefGoogle Scholar
  8. 8.
    Kandall SR. Substance and shadow: women and addiction in the United States. Cambridge, MA: Harvard University Press; 1999.Google Scholar
  9. 9.
    Webb v. United States, 249 US. 96, 99. 1919.Google Scholar
  10. 10.
    Kreek MJ, Vocci FJ. History and current status of opioid maintenance treatments: blending conference session. J Subst Abus Treat. 2002;23:93–105.CrossRefGoogle Scholar
  11. 11.
    Kreek MJ. Rationale for maintenance pharmacotherapy of opiate dependence. Res Publ Assoc Res Nerv Ment Dis. 1992;70:205–30.PubMedGoogle Scholar
  12. 12.
    Andrilla CHA, Coulthard C, Larson EH. Barriers rural physicians face prescribing buprenorphine for opioid use disorder. Ann Fam Med. 2017;15(4):359–62.CrossRefGoogle Scholar
  13. 13.
    Korthuis PT, McCarty D, Weimer M, Bougatsos C, Blazina I, Zakher B, et al. Primary care-based models for the treatment of opioid use disorder: a scoping review. Ann Intern Med. 2017;166(4):268–78.CrossRefGoogle Scholar
  14. 14.
    Bassuk EL, Hanson J, Greene RN, Richard M, Laudet A. Peer-delivered recovery support services for addictions in the United States: a systematic review. J Subst Abus Treat. 2016;63:1–9.CrossRefGoogle Scholar
  15. 15.
    Sordo L, Barrio G, Bravo MJ, Indave BI, Degenhardt L, Wiessing L, et al. Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies. BMJ. 2017;357:j1550.  https://doi.org/10.1136/bmj.j1550.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Yarborough BJ, Stumbo SP, McCarty D, Mertens J, Weisner C, Green CA. Methadone, buprenorphine and preferences for opioid agonist treatment: a qualitative analysis. Drug Alcohol Depend. 2016;160:112–8.CrossRefGoogle Scholar
  17. 17.
    Sullivan MA, Bisaga A, Pavlicova M, et al. A randomized trial comparing extended-release injectable suspension and oral naltrexone, both combined with Behavioral therapy, for the treatment of opioid use disorder. Am J Psychiatry. 2018;176(2):129–37.CrossRefGoogle Scholar
  18. 18.
    Tanum L, Solli KK, Latif ZE, Benth JŠ, Opheim A, Sharma-Haase K, Krajci P, Kunøe N. Effectiveness of injectable extended-release naltrexone vs daily buprenorphine-naloxone for opioid dependence: a randomized clinical noninferiority trial. JAMA Psychiat. 2017;74:1197–205.CrossRefGoogle Scholar
  19. 19.
    Lee JD, Nunes EV Jr, Novo P, Bachrach K, Bailey GL, Bhatt S, et al. Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): a multicentre, open-label, randomised controlled trial. Lancet. 2018;391(10118):309–18.CrossRefGoogle Scholar
  20. 20.
    Burns RM, Pacula RL, Bauhoff S, et al. Policies related to opioid agonist therapy for opioid use disorders: the evolution of state policies from 2004 to 2013. Subst Abus. 2016;37(1):63–9.  https://doi.org/10.1080/08897077.2015.1080208. PMID:26566761.CrossRefPubMedGoogle Scholar
  21. 21.
    Schwartz RP. When added to opioid agonist treatment, psychosocial interventions do not further reduce the use of illicit opioids: a comment on Dugosh et al. J Addict Med. 2016;10(4):283–5.CrossRefGoogle Scholar
  22. 22.
    Dugosh K, Abraham A, Seymour B, McLoyd K, Chalk M, Festinger D. A systematic review on the use of psychosocial interventions in conjunction with medications for the treatment of opioid addiction. J Addict Med. 2016;10:91–101.PubMedCentralGoogle Scholar
  23. 23.
    Substance Abuse and Mental Health Services Administration. Medications for opioid use disorder. Treatment improvement protocol (TIP) series 63, full document. HHS publication no. (SMA) 18- 5063FULLDOC. Rockville: Substance Abuse and Mental Health Services Administration; 2018.Google Scholar
  24. 24.
    Honein MA, Boyle C, Redfield RR. Public health surveillance of prenatal opioid exposure in mothers and infants. Pediatrics. 2019;143(3):e20183801.CrossRefGoogle Scholar
  25. 25.
    Berghella V, Lim PJ, Hill MK, Cherpes J, Chennat J, Kaltenbach K. Maternal methadone dose and neonatal withdrawal. Am J Obstet Gynecol. 2003;189:312–7.CrossRefGoogle Scholar
  26. 26.
    Wachman EM, Schiff DM, Silverstein M. Neonatal abstinence syndrome: advances in diagnosis and treatment. JAMA. 2018;319:1362–74.CrossRefGoogle Scholar
  27. 27.
    LaRose AT, Jones HE. Women’s health and pregnancy. In: Renner JA, Levounis P, LaRose AT, editors. Office-based buprenorphine treatment of opiate use disorder. 2nd ed. Arlington, VA: American Psychiatric Association Publishing; 2018.Google Scholar
  28. 28.
    Zuspan FP, Gumpel JA, Mejia-Zelaya A, Madden J, Davis R. Fetal stress from methadone withdrawal. Am J Obstet Gynecol. 1975;122:43–6.CrossRefGoogle Scholar
  29. 29.
    Rementeriá JL, Nunag NN. Narcotic withdrawal in pregnancy: stillbirth incidence with a case report. Am J Obstet Gynecol. 1973;116:1152–6.CrossRefGoogle Scholar
  30. 30.
    Bell J, Towers CV, Hennessy MD, et al. Detoxification from opiate drugs during pregnancy. Am J Obstet Gynecol. 2016;215:374.e1–6.CrossRefGoogle Scholar
  31. 31.
    Klaman SL, Isaacs K, Leopold A, Perpich J, Hayashi S, Vender J, et al. Treating women who are pregnant and parenting for opioid use disorder and the concurrent care of their infants and children: literature review to support national guidance. J Addict Med. 2017;11:178–90.CrossRefGoogle Scholar
  32. 32.
    Hadland SE, Wharam JF, Schuster MA, Zhang F, Samet JH, Larochelle MR. Trends in receipt of buprenorphine and naltrexone for opioid use disorder among adolescents and young adults, 2001–2014. JAMA Pediatr. 2017;171(8):747–55.CrossRefGoogle Scholar
  33. 33.
    Gomes T, Tadrous M, Mamdani MM, Paterson JM, Juurlink DN. The burden of opioid-related mortality in the United States. JAMA Netw Open. 2018;1(2):e180217.  https://doi.org/10.1001/jamanetworkopen.2018.0217.CrossRefPubMedPubMedCentralGoogle Scholar
  34. 34.
    Levy SJ, Williams JF. Committee on substance use and prevention substance use screening, brief intervention, and referral to treatment. Pediatrics. 2016;138(1):e20161211.  https://doi.org/10.1542/peds.2016-1211.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2020

Authors and Affiliations

  1. 1.Monroe County Health DepartmentMonroe CountyUSA
  2. 2.Department of Family MedicineUniversity of Rochester Medical CenterRochesterUSA

Personalised recommendations